Axsome's valuation is driven by its promising pipeline, with Auvelity as a proven commercial success and Symbravo and AXS-12 showing solid potential. Recent setbacks include the FDA's refusal to file ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback